Price movement over the last 24 hours
ADMA Biologics Inc vs Applied Digital Corporation — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Applied Digital Corporation trades at $31.2 (market cap $8.78B). The key difference: Applied Digital Corporation is far larger — about 4.1× ADMA Biologics Inc's market cap, and Applied Digital Corporation is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | APLD | |
|---|---|---|
Market Cap | $2.13B | $8.78B |
Sector | Health | Technology |
52-Week High | $20.38 | $49.65 |
52-Week Low | $7.60 | $9.18 |
Enterprise Value | $2.20B | $9.87B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Applied Digital (APLD) trades at $33.50, up 1.33% with a bearish technical signal despite bullish oscillators. The company shows rapid revenue growth but significant losses, with a -58.38% net margin and negative cash flow from operations. Recent developments include major AI data center expansions and $36 billion in contracted backlog, though profitability remains elusive amid heavy capital spending.
Outlook remains speculative with strong analyst support (100% buy ratings, $71.43 target) but substantial execution risks. The stock offers high-growth AI infrastructure exposure but faces customer concentration, mounting debt, and uncertain path to profitability. Current valuation at 27x sales appears rich given negative earnings and cash flow challenges.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.
Read more on APLD →